Skip to main content
Springer Nature Link
Account

Table 1 Data for non-constant combination, percentage of cell death, and combination index (CI) for NG and DOX following a 24-hour treatment

From: Naringin mitigated doxorubicin-induced kidney injury by the reduction of oxidative stress and inflammation with a synergistic anticancer effect

IC50 ratio (DOX:NG)

HCT116

Hep-2

Dose(µg/ml)

Death %

CI

Dose(µg/ml)

Death %

CI

1: 1*

11.70:37.94

69.38

0.45*

10.15:50.58

72.42

0.29*

1: 2

11.70:75.88

72.91

0.55

10.15:101.16

75.15

0.36

1: 3

11.70:113.82

75.21

0.64

10.15:151.74

77.97

0.38

1: 4

11.70:151.76

81.39

0.47

10.15:202.32

82.26

0.30

¾: 1*

8.77:37.94

61.78

0.76*

7.61:50.58

67.84

0.39*

¾: 2

8.77:75.88

65.14

0.97

7.61:101.16

71.73

0.46

¾: 3

8.77:113.82

67.49

1.15

7.61:151.74

72.90

0.59

¾: 4

8.77:151.76

70.20

1.21

7.61:202.32

73.10

0.74

½: 1

5.85:37.94

50.93

1.52

5.07:50.58

54.02

1.02

½: 2

5.85:75.88

53.80

2.0

5.07:101.16

60.38

1.07

½: 3

5.85:113.83

57.91

2.1

5.07:151.74

65.72

1.01

½: 4

5.85:151.76

62.07

2.1

5.07:202.32

67.54

1.13

  1. *The optimal CI and cell death percentage for the non-constant combination ratio that was selected for cell and molecular analysis. CI < 1 synergistic, CI > 1 antagonistic, and CI = 1 additive
Back to article page